Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials

PURPOSE: To evaluate 1-year efficacy, durability, and safety of faricimab among patients from Asian countries in the TENAYA/LUCERNE trials of neovascular age-related macular degeneration (nAMD). METHODS: Treatment-naïve patients with nAMD were randomly assigned (1:1) to faricimab 6.0 mg up to every...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kanji, Cheung, Chui Ming Gemmy, Iida, Tomohiro, Lai, Timothy Y. Y., Ohji, Masahito, Yanagi, Yasuo, Kawano, Mika, Ohsawa, Shino, Suzuki, Tomoyuki, Kotecha, Aachal, Lin, Hugh, Patel, Vaibhavi, Swaminathan, Balakumar, Lee, Won Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Retinal Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251323/
https://www.ncbi.nlm.nih.gov/pubmed/37294433
http://dx.doi.org/10.1007/s00417-023-06071-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251323/
https://www.ncbi.nlm.nih.gov/pubmed/37294433
http://dx.doi.org/10.1007/s00417-023-06071-8

Ejemplares similares